15005
document
EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID . Computed tomography ( CT ) , electroencephalograms ( EEG ) , clinical and psychometric data were obtained in 96 mildly to moderately demented patients ( 72 women , 24 men ) , aged 61-96 years ( mean 82 ) , diagnosed according to DSM-III criteria . Patients were off drugs for at least 2 weeks and subdiagnosed according to the modified Marshall-Hachinski ischemic score and CT in 45 senile dementia of the Alzheimer type ( SDAT ) and 51 multiinfarct dementia ( MID ) patients . Evaluations were carried out before and 12 weeks after treatment with either 100 mg denbufylline BID or placebo and included EEG mapping , the Sandoz Clinical Assessment Geriatric ( SCAG ) score/factors , the Clinical Global Impression ( CGI ) , the Digit Symbol Substitution Test ( DSST ) , the Trail-Making Test ( TMT ) and the Digit Span Test ( DS ) . Descriptive data analysis including confirmatory statements found delta/theta activity enhanced , alpha and beta activity reduced , total power augmented , and the centroid slowed down over various brain regions in patients as compared with controls . The two subtypes of dementia could be differentiated in some conventional EEG variables but mostly by means of power asymmetry indices . Denbufylline induced a statistically significant and clinically relevant improvement in both SDAT and MID patients , whereas after placebo this was not the case in CGI , the TMT , and the DS , with interdrug differences being significant in all primary target variables such as the CGI , MMS , SCAG , and DSST . Thus , both the degenerative and vascular type of dementia exhibited a therapeutic benefit that could be objectified at the neurophysiological level by EEG mapping in an improvement of vigilance .
15006
Intervention_Pharmacological
denbufylline
15007
Intervention_Pharmacological
denbufylline
15008
Intervention_Control
placebo
15009
Intervention_Pharmacological
Denbufylline
15010
Intervention_Control
placebo
15011
Outcome_Physical
delta/theta activity
15012
Outcome_Physical
alpha and beta activity
15013
Outcome_Physical
total power
15014
Outcome_Physical
centroid
15015
Outcome_Other
improvement in both SDAT and MID
15016
Participant_Condition
SDAT
15017
Participant_Condition
MID
15018
Participant_Sample-size
96
15019
Participant_Condition
demented
15020
Participant_Sample-size
72
15021
Participant_Sex
women
15022
Participant_Sample-size
24
15023
Participant_Sex
men
15024
Participant_Age
aged 61-96 years ( mean 82 )
15025
Participant_Sample-size
45
15026
Participant_Condition
senile dementia
15027
Participant_Condition
Alzheimer type
15028
Participant_Condition
SDAT
15029
Participant_Sample-size
51
15030
Participant_Condition
multiinfarct dementia
15031
Participant_Condition
MID